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ABSTRACT  
 
Thymosin β4 (TB4) is a pleiotropic actin-sequestering polypeptide that is involved in wound healing and 
developmental processes. TB4 gene silencing promotes differentiation of neural stem cells whereas TB4 
overexpression initiates cortical folding of developing brain hemispheres. A role of TB4 in malignant gliomas 
has not yet been investigated. 
We analyzed TB4 staining on tissue microarrays and performed interrogations of the REMBRANDT and the 
TCGA databases. We investigated TB4 expression in 7 established glioma cell lines and 7 glioma-initiating 
cell lines and induced or silenced TB4 expression by lentiviral transduction in LNT-229, U87MG and GS-2 
cells to study the effects of altered TB4 expression on gene expression, growth, clonogenicity, migration, 
invasion, self-renewal and differentiation capacity in vitro, and tumorigenicity in vivo.  
TB4 expression increased with grade of malignancy in gliomas. TB4 gene silencing in LNT-229 and U87MG 
glioma cells inhibited migration and invasion, promoted starvation-induced cell death in vitro and enhanced 
survival of glioma-bearing mice. TB4 gene silencing in GS-2 cells inhibited self-renewal and promoted 
differentiation in vitro and decreased tumorigenicity in vivo. Gene expression analysis suggested a TB4-
dependent regulation of mesenchymal signature genes and modulation of TGF-β and p53 signaling networks. 
We conclude that TB4 should be explored as a novel molecular target for anti-glioma therapy. 
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INTRODUCTION  
 
Glioblastomas are highly aggressive primary brain tumors thought to originate from neural stem or progenitor 
cells (Chen et al. , 2012, Galli et al. , 2004, Liu et al. , 2010, Zheng et al. , 2008). Despite recent advances in 
multimodal treatment approaches including surgery, radiotherapy and chemotherapy, the median overall 
survival of glioblastoma patients is still poor, i.e. in the range of 16 months in selected clinical trial 
populations (Gilbert et al. , 2011, Stupp et al. , 2005) and approximately 11 months in population-based 
studies (Johnson and O'Neill, 2012). Recently, sub-groups of malignant gliomas have been defined according 
to gene expression signatures. Increased invasiveness and poor prognosis were found to be associated with a 
mesenchymal gene expression signature, whereas expression of genes associated with neural differentiation 
was associated with improved patient survival (Verhaak et al. , 2010). Furthermore, the expression of a 
mesenchymal gene signature was reported to be characteristic of a sub-population of glioma cells termed 
glioma stem-like or glioma-initiating cells (GIC) (Carro et al. , 2010). These cells are believed to promote 
malignancy and evasion from conventional therapies (Bao et al. , 2006, Chen et al. , 2012, Singh et al. , 
2004). GIC exhibit features of neural stem cells (Galli et al. , 2004), and induction of differentiation in the 
GIC sub-population might be a potential therapeutic approach to glioblastoma.  
Thymosin β4 (TB4) is the most abundantly expressed member of the β-thymosin family of small pleiotropic 
polypeptides. Beta thymosins were first isolated from calf thymus and thought to be thymic hormons (Low et 
al. , 1979). However, the first reported cellular function of β-thymosins was buffering of actin monomers 
(Safer et al. , 1990). To date, numerous functions beyond actin sequestering have been identified. For 
example, TB4 gene silencing in the heart led to a reduced number of mesenchymally differentiated cells and 
decreased migration of differentiated cells from the epicardial stem cell niche into the heart muscle, both 
during development and healing of ischemic wounds (Bock-Marquette et al. , 2004). Furthermore, TB4 
activates epicardial stem cells and promotes reprogramming of cardiac fibroblasts to induced pluripotent stem 
cells (Qian et al. , 2012, Smart et al. , 2007). In the developing brain, TB4 expression is tightly associated 
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with neurogenesis and regulates expansion of the stem cell pool of the early neuroepithelium (Roth et al. , 
1999, Wirsching et al. , 2012), whereas TB4 gene silencing promotes the differentiation of neural stem cells 
in vitro (Mollinari et al. , 2009). A role for TB4 has also been suggested in certain brain diseases. TB4 
expression increased after focal brain ischemia (Vartiainen et al. , 1996) and after transient global hypoxia 
(Kim et al. , 2006) in the rat, while proteomic analysis showed increased TB4 protein levels in the 
cerebrospinal fluid (CSF) of patients with Creutzfeldt-Jakob disease (Mohring et al. , 2005). The pivotal role 
of TB4 in promoting cellular invasion and its role in brain development prompted us to investigate a putative 
involvement of TB4 in glioma pathogenesis. 
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MATERIALS AND METHODS  
 
Tissue specimen and tissue microarray (TMA) construction 
Immunohistochemical stainings for TB4 expression were performed on a tissue microarray (TMA) 
comprising 89 surgical glioma samples collected from patients who were treated at the Department of 
Neurosurgery, University Hospital of Zurich, Zurich, Switzerland between 06/2003 and 05/2009. All tumors 
were classified and graded according to the WHO classification of tumors of the central nervous system. For 
semi-quantitative analysis of TB4 staining intensity, we graded TB4 staining arbitrarily from 0-3 (0: negative, 
1: weak, 2: moderate, 3: strong) for each tumor compartment, i.e. endothelial cells, inflammatory host cells 
and tumor cells. Compartments were identified based on morphology. Confirmatory immunohistological 
stainings were performed using antibodies against CD31 for endothelial cells, CD45 and CD11b for 
inflammatory host cells, and glial fibrillary acidic protein (GFAP) for tumor cells. In addition, we graded TB4 
staining arbitrarily for each tissue sample from 0-3, based on the fraction of moderately or strongly TB4 
positive cells (0: less than 20 %, 1: 20-50 %, 2: 50-80%, 3: more than 80% TB4 positive cells, respectively). 
Examples for weak/negative staining versus moderate/strong staining are given in Supplementary Fig. 1A. 
 
Database interrogations 
Publically available microarray and clinical data of glioma patients were acquired from the REpository for 
Molecular BRAin Neoplasia DaTa (REMBRANDT) using the data set available on May 19, 2011 (NCI, 
2005) and from The Cancer Genome Atlas (TCGA) using the data set available on December 15, 2012 
(McLendon et al. , 2008). Gene expression and Kaplan-Meier survival data were queried following the 
REMBRANDT site’s instructions for “advanced search“ and via the caINTEGRATOR homepage 
(https://caintegrator2.nci.nih.gov) following the site’s instructions. The sample group for gene expression was 
restricted to WHO grade II/III gliomas (n = 184) and glioblastomas (n = 220). Survival data for the Kaplan-
Meier analysis using the REMBRANDT database were retrieved for glioblastoma (n = 182). Samples with a 
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0.5-fold down-regulation or a 2-fold up-regulation of the target gene compared to median expression levels 
were defined as up- or down-regulated, the other samples were defined as intermediate.  
Kaplan-Meier survival data from TCGA (n=465) were queried via the R2 microarray analysis and 
visualization platform (http://hgserver1.amc.nl/cgi-bin/r2/main.cgi). The averaged mRNA expression staining 
was scaled to 4775.5 for TMSB4X and 12.5 for TMSB4Y. The cut-off for the highest impact on survival was 
7617.2 for TMSB4X and within the male population (n=311) 9.5 for TMSB4Y.  
For analysis of functional gene interactions, combined confidence scores were generated for each putative 
interaction by integration of experimental and predicted data using the Search Tool for the Retrieval of 
Interacting Genes/Proteins (STRING) Version 9.0 at http://string-db.org (Szklarczyk et al. , 2011). Highest 
confidence settings were applied, thus merely integrating combined scores higher than 0.900. Cluster analysis 
was performed by application of the MCL algorithm. 
 
Cell culture 
LN-18, LNT-229 and LN-308 glioma cell lines were kindly provided by Dr. N. de Tribolet (Lausanne, 
Switzerland). T98G, U87MG and A172 glioma cell lines were purchased from the American Type Culture 
Collection (Manassas, VA). The TU159 cell line was generated in our laboratory (Bahr et al. , 2003). GS-2, 
GS-3, GS-4, GS-5, GS-7, GS-8 and GS-9 GIC lines were provided by Dr. Katrin Lamszus (Gunther et al. , 
2008). All conventional cell lines were cultured in Dulbecco’s modified Eagle’s medium (DMEM) (Radnor, 
PA) containing 10% fetal calf serum (FCS), 2 mM glutamine and penicillin (100 IU/ml)/streptomycin (100 
µg/ml). All GIC lines were cultured in Neurobasal-A medium supplemented with B27 (Invitrogen, Carlsbad, 
CA), 10 ng/ml basic fibroblast growth factor (bFGF), and 10 ng/ml epidermal growth factor (EGF) (BD 
Biosciences, Franklin Lakes, NJ). Growth factors were replenished twice weekly. Conditioned supernatants 
were generated by seeding 2 million cells in T75 flasks overnight, then washing three times and adding 
serum-free DMEM for conditioning for 72 h. 
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Lentiviral constructs 
An shRNA expression cassette for targeting TB4 or a scrambled sequence were cloned into a custom-made 
SEW-based lentivirus (Demaison et al. , 2002) under control of the U6-promoter. For targeting TB4, the 
following sequences were used: 5’-CTGAGATCGAGAAATTCGATAAG-3’ which is highly conserved and 
orthologue in mouse and human TMSB4X (Smart et al. , 2007) and the sequence 5’- 
TGGCTGAGATCGAGAAATT-3’ (si_2). Both constructs were designed to co-express monomeric dsRed 
under the control of the SFFV-promoter to assess the efficacy of stable transduction. The original GFP 
cassette from the SEW vector was excised. For TB4 overexpression, the coding sequence of hTMSB4X was 
cloned into a custom-made SEW-based lentivirus under the control of the SFFV-promoter (Demaison et al. , 
2002), followed by the coding sequences of an 2A-autocleavage site, monomeric dsRed and WPRE. 
Lentivirus was produced and titred (Tabatabai et al. , 2010) and target cells were transduced at a multiplicity 
of infection (MOI) of 100 transducing lentiviral particles per cell. 
 
Quantitative reverse transcriptase PCR 
Total RNA was prepared using the NucleoSpin System (Macherey-Nagel, Düren, Germany) and cDNA 
transcribed using Superscript II reverse transcriptase (Invitrogen). For real-time PCR, cDNA amplification 
was monitored using SYBRGreen chemistry on the 7300 Real time PCR System (Applied Biosystems, Zug, 
Switzerland). The conditions for these PCR reactions were: 40 cycles, 95°C/15 sec, 60°C/1 min, using the 
following specific primers: Arf1 fwd: 5'- GACCACGATCCTCTACAAGC-3', Arf1 rv: 5'-
TCCCACACAGTGAAGCTGATG-3'; TB4 fwd: 5'-AAACCCGATATGGCTGAGAT-3’, TB4 rv: 5'-
TGCTTCTCCTGTTCAATCGT-3', TB15A fwd: 5'-GCCTCCCAACAGCAGATTTCGA-3', TB15A rv: 5'-
ACAGCATCTGCCATCTGGAACA-3', TB15B fwd: 5'-TCCTCCAAAGAGCAGATTTCAG-3', TB15B rv: 
5'-GCATCTGCCATTTGGAATTTACA-3', TGFB1 fwd: 5'-GCCCTGGACACCAACTATTG-3', rev: 5'-
CGTGTCCAGGCTCCAAATG-3', TGFB2 fwd: 5'- AAGCTTACACTGTCCCTGCTGC-3', rev: 5'-
TGTGGAGGTGCCATCAATACCT-3'. Arf1 transcript levels were used as a house-keeping reference for 
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relative quantification of mRNA expression levels using the ΔCT method. The samples for normal brain 
cDNA were purchased from Ambion (Ambion, Applied Biosystems, Foster City, CA). 
 
Reporter assay 
TGF-β-induced signalling was assessed by reporter assays using the SMAD-binding elements (SBE) 
containing reporter plasmid pGL3-SBE4-Luc (Zawel et al. , 1998) kindly provided by Dr. B. Vogelstein 
(Baltimore, MD), and the TGF-β-responsive plasminogen activator inhibitor 1 promoter fragment containing 
the reporter plasmid pGL2-3TP-Luc (Wrana et al. , 1992), which was kindly provided by Dr. J. Massague 
(New York, NY). Dual luciferase/renilla assays were performed with co-transfection of 150 ng of the 
respective reporter construct and 20 ng of pRL-CMV. Luciferase activity was measured using a Mithras LB 
940 microplate reader (Berthold, Bad Wildbad, Germany) and normalized to constitutive renilla activity 
(pRL-CMV). 
 
Immunoblot analysis  
Denatured whole protein lysates (20 µg/lane) were separated on 10-13% acrylamide gels. After transfer to 
nitrocellulose (Biorad, Hercules, CA), blots were blocked in PBS containing 5% skim milk and 0.05% Tween 
20 and incubated overnight at 4°C with primary antibodies, washed in PBS and incubated for 1 h at room 
temperature with secondary antibodies. Primary antibodies were anti-TB4 (Immundiagnostik, Bensheim, 
Germany), anti-ILK (Lab Force, Nunningen, Switzerland) and anti-(p)Akt (Bioconcept, Allschwil, 
Switzerland). Visualization of protein bands was accomplished using horseradish peroxidase-coupled 
secondary antibodies (Santa Cruz Biotechnology, Santa Cruz, CA) and the enhanced chemiluminescence 
(ECL) technique (Thermo Fisher Scientific). 
 
Enzyme-linked immunosorbent assay (ELISA) 
Thymosin β4 in glioblastoma 
9 
 
Conditioned supernatants were generated as described above. Next, 1N HCl was added for 20 min to activate 
latent TGF-β. TGF-β1 and TGF-β2 protein levels were assessed by a commercially available ELISA kit (R&D 
Systems). Streptavidine-horseradisch peroxidase was added for 20 min, then after washing substrate solution 
was added for another 20 min and optical density was measured at 450 nm using a Mithras LB 940 microplate 
reader (Berthold). The standard curve was calculated using recombinant TGF- β1 and TGF-β2 at pre-defined 
concentrations, and a computer generated 4-PL curve-fit (Excel, Microsoft, Seattle, WA). 
 
Flow cytometry  
All flow cytometry analyses were performed using a CyAN ADP flow cytometer (Beckman Coulter, Brea, 
CA). For cell cycle analysis, cells were washed, resuspended in PBS and fixed by slowly adding ice-cold 
ethanol to a final concentration of 70% and incubation on ice for 60 min. Cells were washed and resuspended 
in buffer (PBS containing 0.5% BSA, 0.02% NaN3, 1 mM EDTA) at 100,000 cells per 30 µl. Cells were 
incubated with 5 µl of a custom-made stock solution containing 2.5 mg/ml propidium iodide (Sigma-Aldrich, 
St. Louis, MO), 0.1 mg/ml RNaseA (Roth, Karlsruhe, Germany) and 0.05% Triton X-100 (Sigma-Aldrich) 
for 30 min at 4°C and subsequently washed and resuspended in buffer. For separation of cells by DNA 
content, a PE laser was used to measure the peak plane. For annexinV-PI analysis, cells were stained with 
propidium iodide (Sigma-Aldrich) and pacific blue-labelled annexinV (Lucerna, Lucerne, Switzerland).  
 
MMP activity assay 
For assessment of MMP activity, the FRET-based SensoLyte 520 MMP Substrate Sampler Kit (Anaspec, 
Fremont, CA) was used. In brief, conditioned supernatants of LNT-229 glioma cells were incubated with the 
substrate QXL520TM-γ-Abu-Pro-Cha-Abu-Smc-His-Ala-Dab(5-FAM)-Ala-Lys-NH238 (Smc=S-Methyl-L-
cysteine). Fluorescence emission was measured in a Mithras LB 940 microplate reader (Berthold) at 
Ex/Em=490 nm/535 nm. A standard curve for quantification was obtained using the pre-cleaved fragment 5-
FAM-Pro-Leu-OH at predefined concentrations. 
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Affymetrix gene chip analysis 
Total RNA was extracted from LNT-229 and U87MG glioma cell lines transfected either with siTB4 or 
scrambled control siRNA using the RNeasy Kit (Qiagen, Hilden, Germany). High RNA quality, as indicated 
by RNA integrity numbers of >9, was assured by using the Agilent 2100 Bioanalyzer (Agilent, Böblingen, 
Germany). RNA samples were processed using the 3’IVT express kit (Affymetrix, Santa Clara, CA) starting 
from a total amount of 100 ng RNA. Labeled cRNA was hybridized to Affymetrix GeneChip Human genome 
U133 2.0 plus arrays, followed by washing, labeling and scanning according to standard protocols. The 
GeneSpring software (Agilent) was used for determination of normalized gene expression values. 
 
Growth, Alamar blue, clonogenicity and sphere formation assays 
For growth assays, 1,000 LNT-229 or U87MG cells, or 5,000 GS-2 cells per well were seeded in 24-well 
plates and triplicates were counted daily. Viable cells were identified using trypan blue dye exclusion.  
For Alamar blue assays (Invitrogen), 1,000 cells were seeded in 96-well plates and supplemented with 10% 
Alamar blue for 1 h. Fluorescence emission of metabolized Alamar blue was measured in a Mithras LB 940 
microplate reader (Berthold at Ex/Em=560 nm/600 nm). For clonogenic survival assays of LNT-229 or 
U87MG, 500 cells were seeded in triplicate in 6-well plates. After 20 days, cells were stained using 0.5% 
crystal violet solution. Colonies of 50 or more cells were counted manually at 10x magnification.  
For sphere formation assays, GS-2 cells were initially separated from each other mechanically and with 
accutase (Chemie Brunschwig, Bale, Switzerland). Cells were then seeded in neurobasal medium 
supplemented with growth factors in 6-well plates at a density of 1 cell per 4 μl and sphere formation was 
assessed by manually counting spheres at 10x magnification after 20 days. Sphere volume was calculated 
based on diameters of spheres assessed in 12 high power fields using ImageJ 1.40g software (NIH, Bethesda, 
MD). 
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Migration and invasion assays 
Migration of glioma cells was measured in transwell migration assays (24 wells, 8 μm pore size; BD 
Biosciences). In brief, 5 x 104 cells in 200 μl serum-free DMEM (SFM) were added to each transwell insert. 
NIH 3T3-conditioned medium (700 µl) was used as a chemoattractant in the lower wells. NIH 3T3 fibroblasts 
secrete a variety of growth factors, and therefore the conditioned medium from these cells is commonly used 
as a chemoattractant (Albini et al. , 1987). After an incubation period of 16 h, the cells on the lower side of 
the membrane were fixed in ice-cold methanol at 4°C, stained with hemalaun, and sealed on slides. 
Quantification of cell migration was expressed as the mean count of stained cells in eleven random fields of 
each membrane. 
For invasion assays, glioma spheroids were generated by incubating 1,000 cells for 72 h in 96-well plates 
precoated with 1% Noble Agar (Difco Laboratories, Detroit, MI). Spheroids with a diameter of approximately 
200 µm were embedded into a collagen matrix containing collagen type I (Invitrogen), 10% FCS and 10% 
NaHCO3 in a 96-well plate. Sprouting of spheroids was monitored by daily photographs or by time-lapse 
video microscopy using a JuLI image viewer (NanoEnTek, Seoul, Korea). For quantitation, the area covered 
by sprouting cells and the median invaded distance of 50 cells were assessed using the ImageJ 1.40g software 
(NIH). The spheroid margin at day 0 was used as a reference point for measurement of the invaded distance 
of sprouting cells. For measurement of the invasion area, the area covered by the spheroid at day 0 was 
subtracted from the overall area that was covered on subsequent days. 
 
Differentiation assay 
For the induction of differentiation, GIC were cultured in full neurobasal medium supplemented with the 
indicated FCS concentrations for 5 days. Differentiation was assessed by counting cells that exhibited an 
adherent phenotype and by immunostaining for glial fibrillary acid protein (GFAP) or nestin.  
 
Animal studies 
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All experiments were performed according to the Swiss animal protection law. CD1nu/nu mice were purchased 
from Charles River Laboratories (Wilmington, MA). Mice aged 8–12 weeks were anesthetized and placed in 
a stereotaxic fixation device. A burr hole was drilled in the skull 2 mm lateral and 1 mm posterior to the 
bregma. The needle of a Hamilton syringe was introduced into a depth of 3 mm (Tabatabai et al. , 2007). 
LNT-229 (75 x 104), U87MG (105) or GS-2 (2 x 105) cells were resuspended in PBS and were injected into 
the right striatum. GS-2 cells were dissociated prior to injection. Animal experiments with LNT-229 gliomas 
were performed twice. Animal experiments with U87 and GS-2 gliomas were performed once. Animals were 
assessed clinically thrice weekly and were sacrificed at a clinical score of 2 (Supplementary Table 1). 
 
Immunocytology, histology and immunohistochemistry 
Primary antibodies were monoclonal mouse anti-Nestin (Zytomed, Berlin, Germany, 1:100), polyclonal rabbit 
anti-GFAP (Dako, Glostrup, Denmark, 1:1000), monoclonal mouse anti-NeuN (Chemicon, Temecula, CA, 
1:100), polyclonal rabbit anti-β-III-Tubulin (R&D Systems, Minneapolis, MN), monoclonal mouse anti-
CD31 (Dako, Glostrup, Denmark, 1:50), monoclonal mouse anti-CD45 (Dako, Glostrup, Denmark, 1:50), 
polyclonal rabbit anti-CD11b (Abcam, Cambridge, UK, 1:50) and polyclonal rabbit anti-Thymosin β4 
(Immundiagnostik, Bensheim, Germany, 1:100). For immunocytochemistry, cells were grown on Poly-D-
Lysine-coated cell culture slides (BD Biosciences) and fixed in PFA. Neurospheres were centrifuged onto 
glass slides using a Shandon Cytospin 4 (Thermo Fisher Scientific, Waltham, MA), dried briefly and fixed in 
PFA. Cells were permeabilized with 0.2% Triton X-100 and 10% normal horse or swine serum (Vector, 
Burlingame, CA) was used for blocking. For conventional histology, 5 µm paraffin sections were stained with 
hematoxylin & eosin. For immunohistochemistry, deparaffinized and rehydrated sections were boiled in 
EDTA buffer, pretreated with 1% H2O2, blocked in 10% swine serum or blocking solution (Candor 
Biosciences, Wangen, Germany). Biotinylated secondary antibodies, streptavidine and diaminobenzidine 
were obtained from Dako and used according to standard procedures.  
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Statistics 
Quantitative data are expressed as mean or median and SEM, as indicated. For column statistics, unpaired t-
test or one-way ANOVA followed by Tukey's post hoc test was performed. The in vitro experiments reported 
here were performed at least three times in triplicate with similar results. For survival statistics Gehan-
Breslow-Wilcoxon test was performed. All statistical analyses were performed using Prism 5 (GraphPad 
Software, La Jolla, CA).
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RESULTS 
 
TB4 is overexpressed in malignant gliomas 
We investigated TB4 levels in malignant gliomas in vivo by immunohistochemistry on a TMA containing 
tissue cores from 89 gliomas of different WHO grades (17 WHO grade II, 24 WHO grade III, 48 WHO grade 
IV) and 4 normal brain tissue control samples. Representative stainings are shown in Figure 1A. The highest 
TB4 levels were observed in glioblastomas (Fig. 1B). We analyzed TB4 staining in 3 different compartments, 
i.e. tumor cells, inflammatory host cells and endothelial cells (Supplementary Fig. 1A-D). This compartment-
specific analysis revealed a correlation of TB4 staining intensities with increasing WHO grade in tumor cells 
(Fig. 1C), but not in inflammatory host cells or endothelial cells (Supplementary Fig. 1C and D). In 
glioblastoma samples, the TB4 staining intensity was higher in tumor cells than in host or endothelial cells 
(Fig. 1D). We also correlated TB4 staining data with clinical parameters (Supplementary Table 2). In 
glioblastomas, TB4 levels did not differ between younger versus older patients (Supplementary Fig. 1E), but 
TB4 levels were higher in recurrent vs primary glioblastomas (Supplementary Fig. 1F). For correlation with 
clinical outcome, we subdivided samples by low (0-2) versus high (>2) arbitrary TB4 levels. Median overall 
survival was lower in the group of patients with strongly TB4 positive glioblastomas (TB4 low: 15.1 months 
vs TB4 high: 9.9 months, p<0.05) (Fig. 1E). A more detailed investigation of TB4 staining and its role for 
clinical outcome in histological glioma subtypes of WHO grades II or III was precluded because of sample 
size.  
To expand and validate our immunohistochemical TB4 data in malignant gliomas, we performed a 
REMBRANDT database interrogation (NCI, 2005). TB4 mRNA expression in gliomas correlated with 
increasing WHO grade (Supplementary Fig. 1G) and glioblastoma patients with low (<0.5-fold of median) 
TB4 expressing tumors had longer overall survival than patients with high (>2-fold of median) TB4 
expressing glioblastomas (Fig. 1F). Correlation of TB4 expression with survival in glioblastoma was further 
confirmed by a TCGA database interrogation (Supplementary Fig. 1H).  
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Considering that the gene coding for TB4 is located on the X-chromosome prompted us to further analyze 
gender differences and expression of the homologous gene TMSB4Y. REMBRANDT and TCGA analyses 
yielded no differences of TMSB4X expression in female or male patients. Moreover, TMSB4Y was expressed, 
if at all, only at very low levels in both datasets, although with a significant correlation to survival in the male 
population (data not shown).  
Next, we analyzed TB4 mRNA expression in 7 established glioma cell lines (T98G, U87MG, LN-18, LNT-
229, LN-308, A172, Tu159) and in 7 GIC cultures (GS-2, GS-3, GS-4, GS-5, GS-7, GS-8, GS-9) using real-
time RT-PCR analysis. TB4 was overexpressed up to 10-fold in all GIC cultures except for GS-4 and up to 
22-fold in all long-term glioma cell lines relative to normal brain tissue samples used for reference 
(Supplementary Fig. 2). Immunocytochemistry indicated nuclear and cytoplasmic localization of TB4 in 
glioma cells, with a specific increase in cytoplasmic protrusions (Fig. 1G).  
 
TB4 gene silencing in glioma cells enhances apoptotic cell death and decelerates clonogenic growth 
To investigate the biological role of TB4 functions in glioma cells, we performed lentiviral shRNA-mediated 
gene silencing (siTB4) in two cell lines with low and high TB4 expression levels, i.e. LNT-229 and U87MG 
(Supplementary Fig. 2, Fig. 2A-B). Assessment of dsRed co-expression revealed lentiviral transduction 
efficacies close to 100% (Supplementary Fig. 3). TB4 gene silencing did not affect the mRNA expression 
levels of thymosin β15 (TB15), another member of the β−thymosin family (data not shown), thus validating 
the specificity of the shRNA sequence used for targeting TB4 and excluding compensatory upregulation of 
TB15. In addition, we overexpressed TB4 in LNT-229 and U87MG cells by lentiviral vectors (Supplementary 
Fig. 4A). 
The growth of LNT-229 cells was increased upon TB4 overexpression (Supplementary Fig. 4B) and 
decreased after TB4 gene silencing (Supplementary Fig. 4C), resulting in doubling times during exponential 
growth of 20.2 h for TB4-overexpressing cells, as compared to 22.1 h for empty vector control cells, and 25.6 
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h for siTB4 cells, as compared to 21.0 h for scr cells. Reduced growth of LNT-229 cells depleted of TB4 was 
paralleled by reduced metabolic activity (Supplementary Fig. 4D).  
One of the key features of cancer cells is survival under nutrient-restricted conditions (Hanahan and 
Weinberg, 2011). Thus, we analyzed cell viability by trypan blue exclusion in LNT-229 and U87MG glioma 
cells after 7 days of serum deprivation. Trypan blue-positive cells, i.e. the dead cell fraction was increased 
upon TB4 gene silencing (Fig. 2C). The effect of TB4 gene silencing on cell death under nutrient-restricted 
conditions was confirmed using a second shRNA sequence (Supplementary Fig. 5A-D). Flow cytometry-
based analysis of the cell cycle indicated a 5-fold increase of the sub-G0/1 fraction in siTB4 cells whereas the 
cell cycle distribution upon starvation in the viable cell fractions was similar in both scr and siTB4 LNT-229 
cells (Fig. 2D and E). In serum-containing cell culture medium, however, dead cell fractions did not differ in 
scr and in siTB4 cells. We then performed annexinV and PI flowcytometry in scr and siTB4 glioma cells to 
analyze whether enhanced starvation-induced cell death of TB4-depleted cells was paralleled by an increase 
in apoptosis. The percentage of apoptotic, i.e. annexinV-positive cells was 3.2-fold (48% vs 15%) higher in 
LNT-229 siTB4 and 2.2-fold (61% vs 28%) higher in U87MG siTB4 cells. The percentage of dead, i.e. PI-
positive cells was 3.9-fold (43% vs 11%) higher in LNT-229 siTB4 and 2.6-fold (55% vs 21%) higher in 
U87MG siTB4 cells (Fig. 2F).  
Next, we analyzed clonogenicity, single colony morphology and actin filament staining in LNT-229 scr and 
siTB4 cells (Fig. 2G-L). After TB4 gene silencing, the number of colonies was not reduced, but single 
colonies were smaller (Fig. 2G and J) and more compact (Fig. 2H and K) and cellular protrusions were 
reduced in size and number (Fig. 2I and L). Similar data were observed in U87MG (data not shown).  
 
TB4 gene silencing inhibits migration and invasion of glioma cells in vitro 
The accumulation of TB4 in cytoplasmic protrusions (Fig. 1G) and the marked reduction of size and number 
of cytoplasmic protrusions in LNT-229 siTB4 cells (Fig. 2L) prompted us to investigate the effects of TB4 on 
migration and invasion in LNT-229 and U87MG cells. We analyzed the invasiveness of LNT-229 scr or 
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siTB4 spheroids (Fig. 3A and B, Supplementary Fig. 5E and F), and U87MG scr or siTB4 spheroids (Fig. 3C 
and D, Supplementary video) in a three-dimensional collagen spheroid invasion assay and assessed invasion 
after 24 h (Fig. 3 E-H, Supplementary Fig. 5G and H) and after 48 h (Fig. 3I-L, Supplementary Fig. 5I and J) 
in a serum-containing collagen matrix. The area covered by invading cells was reduced by 2.7-fold in LNT-
229 siTB4 and by 4.2-fold in U87MG siTB4 cells (Fig. 3M). The invaded distance was reduced by 2.3-fold in 
LNT-229 siTB4 and by 4.1-fold in U87MG siTB4 cells (Fig. 3N). Similar results were observed after 
targeting TB4 with a second shRNA sequence in LNT-229 (Supplementary Fig. 5K and L). Transwell 
migration of LNT-229 and U87MG cells was decreased upon TB4 gene silencing and increased upon TB4 
overexpression (Supplementary Fig. 6), but no effect of TB4 overexpression on spheroid invasion was 
observed (data not shown). 
 
TB4 gene silencing prolongs symptom-free survival of glioma-bearing mice in vivo 
We orthotopically implanted LNT-229 or U87MG scr or siTB4 cells into nude mice. The latency until the 
onset of neurological symptoms was prolonged in animals bearing TB4-depleted experimental gliomas (Fig. 
4A and B). The median time interval until the onset of symptoms was increased from 44 to 56 days (p<0.05) 
in LNT-229 glioma-bearing animals, and 45 to 54 days (p<0.05) in U87MG glioma-bearing animals. 
Histological analysis revealed smaller and less invasive tumors in siTB4 gliomas, and tumor volume was 
markedly reduced to approximately 20-30% at day 28 (Fig. 4C). At the onset of neurological symptoms, 
however, tumor size was similar in LNT-229 scr and siTB4 gliomas (Supplementary Fig. 7). 
 
A TB4-dependent transcriptional network involves modulation of TGF-β signaling and regulates 
mesenchymal signature genes in glioma cells 
Next, we aimed at analyzing the mechanism by which TB4 exerts its effects in glioma cells. First, we 
assessed integrin-linked kinase (ILK), Akt and matrix metalloproteinase (MMP)-2 expression after TB4 
knockdown, because stabilization of ILK, phosphorylation of Akt and consecutive regulation of MMP2 
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expression by TB4 have been suggested in other cell types (Bock-Marquette et al. , 2004, Fan et al. , 2009). 
ILK protein levels were not decreased in LNT-229 siTB4 glioma cells and there was no effect of TB4 gene 
silencing on Akt phosphorylation on Ser473 (Supplementary Fig. 8A). We reasoned that phosphoinositide 3-
kinase (PI3K) signaling might compensate for effects of siTB4 on ILK levels, because PI3K is a major ILK 
activator. Indeed, upon treatment with the PI3K inhibitor wortmannin ILK protein levels were reduced in 
TB4-depleted cells, but with yet no effect on Akt phosphorylation. MMP2 protein levels remained unaffected 
upon TB4 gene silencing, too (Supplementary Fig. 8B), but MMP-activity was reduced in an assay that 
detects the activity of multiple MMP (MMP 1/2/3/7/8/9/12/13/14) (Supplementary Fig. 8C). These results 
indicate that TB4 stabilizes ILK in glioma cells and alters MMP activity, but does not affect Akt 
phosphorylation. 
To understand the molecular network controlled by TB4 in glioma cells, we performed an Affymetrix chip-
based transcriptome analysis of LNT-229 scr and siTB4 cells and retrieved a list of regulated candidate genes. 
At a 2.0 fold-change cut-off, 1.724 probe sets were differentially detected, including 162 that were directed 
against a total of 116 cDNAs coding for transcription factors (Supplementary Table 3). Submission of all 
differentially expressed transcription factors to the Search Tool for the Retrieval of Interacting Genes/Proteins 
(STRING) identified 2 main clusters (Fig. 5A). One cluster involved mainly genes interacting with TP53 
(green nodes), the other cluster was centered around the downstream TGF-β signaling modulators EP300 and 
FOS (red nodes). The latter cluster furthermore comprised the TGF-β signaling modulators CITED1 and 
CITED2, and interacted with a third cluster comprising the TGF-β signaling modulators SMAD6 and SMAD7 
(brown nodes). All 6 identified TGF-β signaling modulators were downregulated in the Affymetrix gene chip 
in siTB4 glioma cells. 
As we had observed enhanced apoptosis and decreased migration and invasion upon TB4 gene silencing 
(Figs. 2 and 3, Supplementary Fig. 5), we performed a gene ontology (GO) analysis with TB4-dependently 
differentially regulated genes. GO annotation identified 34 genes involved in migration (Supplementary Table 
4) and 75 genes involved in apoptosis (Supplementary Table 5), with an overlap of 14 genes that are 
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annotated to both processes, including the TGF-β signaling modulators TGFB2, THBS1, CITED 2 and 
SMAD7. Furthermore, inhibitors of TGF-β signaling including ONECUT2 and FBN1 were up-regulated in 
LNT-229 siTB4 cells. Conversely, TGF-β signaling transcriptional target genes including SNAI2, IRX1, 
FBXO32, DAPK1, ATG5, ATG7, TGFA, PDGFC, COL1A2 and FN1 were downregulated upon TB4 gene 
silencing. 
The central role of TGF-β signaling in gliomas prompted us to further validate it by qRT-PCR, ELISA and 
reporter assays. TGFB1 mRNA levels were reduced in LNT-229 siTB4 cells by 2.2-fold and in U87MG 
siTB4 cells by 3.6-fold (Supplementary Fig. 9A). TGFB2 mRNA levels were reduced in LNT-229 siTB4 cells 
by 4.3-fold and in U87MG siTB4 cells by 18.3-fold, respectively (Supplementary Fig. 9B). The levels of 
TGF-β1 and TGF-β2 protein in the supernatants of LNT-229 siTB4 were decreased by 1.4-fold and 4.5-fold, 
respectively (Supplementary Fig. 9C and D). Furthermore, decreased TGF-β signaling in LNT-229 siTB4 was 
confirmed using a dual luciferase/renilla reporter assay (Supplementary Fig. 9E). 
Inhibition of TGF-β signaling inhibits stem cell properties and promotes a more differentiated gene 
expression pattern of glioma cells due to decreased expression of the Sry-related HMG-box factor SOX2 
(Ikushima et al. , 2009) and SOX2 was down-regulated in TB4-depleted LNT-229 cells (Supplementary Table 
3). Thus, we compared the expression signature of TB4-depleted cells with recently established signatures of 
gliomas that take into account levels of differentiation (Carro et al. , 2010, Freije et al. , 2004, Phillips et al. , 
2006, Verhaak et al. , 2010). A comparison of the signature of TB4-depleted cells with the signatures 
suggested by Freije and colleagues (2004) revealed up-regulation of the neurogenesis signature genes BMP2 
and HEY2, whereas the invasive signature genes COL6A3, THBS1 and FN1 and the proliferative signature 
genes TOP2A, CDKN3, PTTG1 and CENPF were down-regulated (Freije et al. , 2004). A comparison with 
the signatures suggested by Phillips and colleagues (2006) revealed an up-regulation of the proneural 
signature gene GABBR1, silencing of the marker genes of the proliferative signature IQGAP3 and HMMR and 
silencing of the mesenchymal signature genes COLA4A1 and COL4A2 (Phillips et al. , 2006). Of note, gene 
silencing of IQGAP3, HMMR, COLA4A1 and COL4A2 is also a feature of the proneural signature, as defined 
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by the centroids of k-means clustering (Phillips et al. , 2006). A shift of the mRNA expression pattern of 
LNT-229 siTB4 cells towards a proneural signature was furthermore apparent when comparing the TB4-
depletion signature with the signatures established by Verhaak and colleagues (2010) (Supplementary Table 
6). 
Based on the sample data classified as proneural, proliferative or mesenchymal in previous studies, Carro and 
colleagues defined a subset of transcription factors which function as master regulators of a mesenchymal 
expression signature, while suppressing a proneural signature in malignant gliomas (Carro et al. , 2010, Freije 
et al. , 2004, Nigro et al. , 2005, Phillips et al. , 2006). Comparison of this comprehensive dataset with the set 
of genes that were differentially regulated in LNT-229 siTB4 cells revealed an up-regulation of 20 genes of 
the proneural signature and silencing of 23 proliferative signature genes (Supplementary Table 7). 
Furthermore, 10 transcription factors that had been predicted by an ARACNe based master regulator 
algorithm to be frequently connected to the mesenchymal signature, or had consensus enrichment in the 
promoters of mesenchymal signature genes (Carro et al. , 2010), respectively, were down-regulated in LNT-
229 siTB4 cells (Fig. 5B). Conversely, the inhibitor of the mesenchymal signature SATB1 was up-regulated 
upon TB4 gene silencing (Fig. 5B). These data indicate that TB4 gene silencing inhibits the mesenchymal 
signature and shifts the balance towards a more differentiated expression pattern. In line with this, a set of 20 
genes that are down-regulated during in vitro astrocyte development were also down-regulated in LNT-229 
siTB4 cells (Supplementary Table 8) (Cahoy et al. , 2008).  
 
TB4 gene silencing in GS-2 cells reduces stemness in vitro and in vivo 
The analyses summarized above suggested that TB4 promotes the mesenchymal signature in glioma cells. To 
further analyze the functional relevance of this finding, we investigated the role of TB4 in the glioma stem-
like cell line GS-2 (Gunther et al. , 2008). We efficiently depleted TB4 expression in GS-2 cells as assessed 
by qRT-PCR and immunoblot (Fig. 6A and B). TB4 depletion decreased cellular growth (Fig. 6C) and sphere 
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formation (Fig. 6D). The sphere volume was reduced in GS-2 siTB4 to 16.12 +/- 1.97 % (p<0.0001) (Fig. 
6E). 
Next, we assessed the differentiation capacity of GS-2 siTB4 versus GS-2 scr cells using increasing FCS 
concentrations as a stimulus to induce differentiation. FCS treatment yielded a maximum of 5.8 + 0.9-fold 
increase (p<0.0001) of cells exhibiting an adherent, differentiated phenotype in GS-2 siTB4 (Fig. 6F). Cells 
that acquired this phenotype expressed glial fibrillary acidic protein (GFAP), but not nestin. Moreover, there 
was a reduction of nestin-positve cells in GS-2 siTB4 spheres as compared with GS-2 scr while the number of 
cells expressing GFAP was increased (Fig. 6G). Representative images of GS-2 scr and siTB4 cells grown as 
spheres or supplemented with 5% FCS for 7 days are shown in Figure 6H and representative stainings of GS-
2 scr and siTB4 cells are outlined in Figure 6I.  
Finally, we assessed the tumorigenicity of GS-2 siTB4 cells in vivo. Even after implantation of 200.000 cells, 
we did not observe any neurological symptoms in GS-2 siTB4-glioma-bearing mice until day 140 whereas 
GS-2 scr-glioma-bearing mice developed neurological symptoms within 69-87 (median 78) days (Fig. 6J). 
After 140 days, we sacrificed the asymptomatic GS-2 siTB4-glioma-bearing animals and analyzed the brains 
by histology. Tumor formation had occurred only in 3 of 7 animals (Fig. 7A and B). The expression of nestin 
was reduced (Fig. 7C and D). Expression of GFAP was similar in both groups (Fig. 7E and F). We did not 
detect the neural lineage marker NeuN in GS-2 scr gliomas (Fig. 7G) whereas NeuN-positive cells were 
present in GS-2 siTB4 gliomas (Fig. 7H). 
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DISCUSSION 
 
TB4 is a key regulator of cancer hallmarks including migration, invasion, cell survival and stem cell 
activation (Bock-Marquette et al. , 2004, Fan et al. , 2009, Smart et al. , 2007). In neural stem cells, TB4 gene 
silencing promotes neural differentiation, whereas overexpression of TB4 in the developing brain leads to an 
expansion of the neuroglial stem and progenitor cell pool and induction of a mesenchymal phenotype 
(Mollinari et al. , 2009, Wirsching et al. , 2012). The sub-population of stem-like cells in gliomas termed GIC 
exhibits features of neuroglial progenitor cells, including self-renewal and multilineage differentiation, and 
expresses a mesenchymal gene signature (Bao et al. , 2006, Carro et al. , 2010, Chen et al. , 2012, Galli et al. , 
2004). The role of TB4 during brain development and for mesenchymal transformation prompted us to 
hypothesize a role of TB4 in malignant glioma. 
As a first step to investigate a role for TB4 in malignant glioma, we performed TMA, REMBRANDT and 
TCGA analyses (Fig. 1, Supplementary Fig. 1). TB4 expression correlated with ascending grades of 
malignancy and with survival. TMA data suggested that the correlation of TB4 staining intensity with 
increasing WHO grade was due to an increase of TB4 staining intensity within the tumor cell compartment 
(Fig. 1, Supplementary Fig. 1). Thus, we focused our further analyses on TB4 in glioma cells.  
Both, long-term glioma and GIC lines expressed high levels of TB4 in vitro (Supplementary Fig. 2). Silencing 
of TB4 in long-term glioma cells promoted apoptotic cell death upon nutrient depletion (Fig. 2, 
Supplementary Fig. 5), inhibited migration and invasion (Fig. 3, Supplementary Fig. 5) and increased survival 
of glioma-bearing nude mice (Fig. 4). Upon the onset of clinical symptoms, LNT-229 siTB4 gliomas 
resemble LNT-229 scr gliomas in terms of tumor size and invasiveness, thus suggesting a compensation for 
TB4 gene silencing in an advanced stages of the disease (Supplementary Fig. 7). 
Alterations of the cellular morphology from spindle-like to a more dense and adhesive pattern upon TB4 
depletion suggested altered actin dynamics to be the underlying mechanism by which TB4 mediates its 
cellular functions (Fig. 2). However, enhanced starvation-induced apoptotic cell death pointed to a functional 
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significance of TB4 beyond its well-established role as an actin-buffering polypeptide (Fan et al. , 2009). 
Thus, we reasoned that alteration of intracellular signaling pathways may contribute to the observed in vitro 
and in vivo effects of TB4 gene silencing in glioma. To further elucidate the underlying mechanism of TB4 
gene silencing-mediated effects, we first investigated known interactions by which TB4 modulates cellular 
functions in other cell types. During cardiac development and in migrating endothelial cells TB4 stabilizes 
ILK, thus promoting Akt phosphorylation and MMP2 expression (Bock-Marquette et al. , 2004, Fan et al. , 
2009). Furthermore, TB4-induced epithelial-mesenchymal transition and malignant progression of colon 
adenoma to carcinoma is mediated by ILK stabilization and activation (Huang et al. , 2007). In turn, TB4 
depletion in colon cancer cells leads to reduced ILK activity, reduced tumor volumes and cell migration 
(Ricci-Vitiani et al. , 2010). In LNT-229 glioma cells, ILK protein levels were not reduced upon TB4 gene 
silencing, unless PI3K signaling was inhibited by wortmannin. However, even strongly decreased ILK protein 
levels did not affect Akt phosphorylation or MMP2 protein level (Supplementary Fig. 8) suggesting 
compensatory mechanisms for down-regulation of ILK.  
To unravel the molecular network of TB4 in glioma cells, we performed a genome-wide screening for genes 
that were differentially transcribed upon TB4 gene silencing (Fig. 5). In the past decade, several molecular 
subgroups of malignant gliomas based on genetic signatures have been defined and correlated to clinical 
outcome (Phillips et al. , 2006, Verhaak et al. , 2010). Expression of proneural marker genes correlates with 
better clinical outcome whereas mesenchymal and proliferative signatures were associated with poor outcome 
(Carro et al. , 2010, Freije et al. , 2004, Phillips et al. , 2006). Consequently, we compared the TB4-
dependently regulated set of genes with the genetic signatures of these previously published molecular 
subgroups. This comparison revealed regulation of various mesenchymal signature genes in the sense of a 
shift towards a more differentiated molecular subgroup in siTB4 cells (Fig. 5, Supplementary Tables 6 and 7).  
As GIC more closely reflect the functional relevance of a shift towards a more differentiated molecular 
subgroup than long-term glioma cell lines (Galli et al. , 2004, Singh et al. , 2004) we analyzed the role of TB4 
expression in the GIC line GS-2 (Gunther et al. , 2008). TB4 depletion in GS-2 cells inhibited self-renewal, 
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decreased sphere size and increased differentiation capacity in vitro (Fig. 6), and strongly reduced 
tumorigenicity and increased differentiation capacity in vivo (Fig. 7). These data are supported by previous 
reports suggesting a role of TB4 for stemness during brain and cardiac development (Bock-Marquette et al. , 
2004, Wirsching et al. , 2012).  
GS-4 cells share molecular features with GS-2 (Gunther et al. , 2008), but, as opposed to GS-2, GS-4 express 
little if any TB4 (Supplementary Fig. 2). In line with our observations on the role of TB4 for stemness and 
differentiation, GS-4 cells are not tumorigenic in nude mice, express lower levels of the progenitor marker 
nestin, higher levels of the differentiation markers MAP2 and BAI1, and exhibit an adherent growth pattern 
(Gunther et al. , 2008). 
Functional interactome analysis of the TB4-dependently regulated set of genes using STRING and subsequent 
cluster analysis revealed a network involving p53 and TGF-β signaling (Fig. 5). Of note, recent studies have 
demonstrated that TGF-β mediates promotion of stemness in gliomas (Anido et al. , 2010), thus suggesting a 
mechanism by which a siTB4-mediated decrease of TGF-β signaling may have decreased stemness in GS-2 
cells (Fig. 6 and 7).  
We further confirmed altered TGF-β signaling by data derived from qRT-PCR, ELISA and reporter assays 
indicating a decreased TGF-β1 and TGF-β2 transcription and signaling upon TB4 depletion (Supplementary 
Fig. 9). One well-established function of TGF-β in gliomas is immunomodulation in the tumor 
microenvironment (Massague, 2008). Immunomodulation, however, is unlikely to have played a significant 
role for the prolonged survival in our orthotopic xenograft models, as these experiments were performed in 
immunodeficient mice (Figs. 4 and 6).  
In summary, TB4 expression correlates with glioma grades and patients’ survival, and regulates key 
malignant features in glioma models, including cell survival, invasiveness and stemness. Thereby, TB4 
modulates core molecular networks including p53 and TGF-β signaling. We conclude that TB4 might be a 
novel key molecule integrating multiple hallmarks and molecular networks in malignant gliomas and should 
thus be further explored as a putative therapeutic target. To date, the only molecular inhibitor known to 
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interfere with TB4 is Photorabdus toxin complex 3, which inhibits the interaction of TB4 with G-actin (Lang 
et al. , 2010), but inhibition of the TB4-actin interaction alone is likely to yield activation of other cancer 
relevant pathways (Fan et al. , 2009). Antisense strategies for targeting gene expression are conceivable, but 
have had limited success in cancer treatment so far. Recently, a first antisense therapy has been approved by 
the United States Food and Drug Administration to target apolipoprotein B in familial hypercholesterolemia 
(Gotto and Moon, 2013). Limitations for such an approach in malignant glioma include tumor heterogeneity 
and the uncertainty of how efficient down-regulation would have to be to exert activity. Yet, the design of 
pharmacological inhibitors of TB4 function seems feasible, given innovative high-throughput screening of 
small molecule libraries (Zhang et al. , 2009). Small molecule inhibitors could either target TB4 function 
directly or its down-stream mediators. Thus, a thorough investigation of molecular interactions in the TB4 
network in gliomas is needed. 
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FIGURE LEGENDS 
 
Fig. 1: TB4 is overexpressed in high-grade gliomas and low TB4 expression correlates with better 
outcome  
A: Representative images of TB4 immunostainings of a TMA comprising 89 gliomas of different WHO 
grades (II-IV) and 4 normal brain control samples (NB). B: x, WHO grade, y, TB4 staining intensity 
(arbitrary units; *p<0.05, **p<0.01). C: TB4 immunoreactivity scores in the tumor cell compartment of WHO 
grade II-IV patients’ samples (***p<0.001). D: TB4 immunoreactivity scores in glioblastoma (GBM, WHO 
grade IV) stratified for tumor cells (TC), endothelial cells (EC) and inflammatory host cells (HC) 
(***p<0.001). E: Survival analysis of patients with glioblastomas (WHO grade IV) subdivided by low (0-2) 
versus high (>2) TB4 staining intensity. F: REMBRANDT survival analysis of patients with glioblastoma 
subdivided by low (<0.5-fold, green, n=6) versus high (>2.0-fold, blue, n=14) TB4 mRNA expression. As a 
reference, all glioblastoma samples are depicted in grey (n=182). G: Immunocytology of LNT-229 glioma 
cells stained for TB4 (green). Nuclei were stained with DAPI (blue). Scale bars: 100 µm (A), 10 µm (E).  
 
Fig. 2: TB4 gene silencing promotes starvation-induced apoptotic cell death of LNT-229 and U87MG 
glioma cells  
A and B: Quantitative RT-PCR (A) and immunoblot (B) analysis of lentiviral TB4 gene silencing (si) relative 
to scrambled control shRNA (scr). C-F: 10,000 cells per well were seeded in 6-well plates overnight and 
cultured in serum-free medium for 7 days. C: LNT-229 scr and si cells were counted manually using trypan 
blue for identification of dead cells. Values are expressed as percent of total scr (mean +/- SEM; **p<0.01, 
***p<0.001, ****p<0.0001). D and E: Propidium iodide (PI) based flow cytometric cell cycle analysis of 
LNT-229 scr (D) and si (E) cells. F: LNT-229 and U87MG scr and si cells were stained with annexinV and 
PI for identification of life (double negative), dead (PI+) and apoptotic (annexinV+) cell fractions. G-L: LNT-
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229 scr and si cells were studied by colony formation assay (G and J), for single colony morphology (H and 
K) and FITC-phalloidin staining of actin filaments (I and L). Arrowheads in I and L indicate cellular 
protrusions. Scale bars: 1 cm (G and J), 100 µm (H and K) and 25 µm (I and L). 
 
Fig. 3: TB4 gene silencing inhibits invasion of LNT-229 and U87MG glioma cells  
A-L:Lentivirally transduced LNT-229 or U87MG cells expressing shRNAs targeted against TB4 (si) or a 
scrambled control (scr) were placed in a three-dimensional collagen I matrix (A-D) and evaluated after 24 h 
(E-H) and 48 h (I-L); scale bar: 200 µm. M and N: The area covered by invading cells (M), or the median 
distance invaded by the 50 most peripheral cells (N) were measured for quantitation after 48 h (mean +/- 
SEM; ***p<0.001, ****p<0.0001). 
 
Fig. 4: TB4 gene silencing delays the onset of neurological symptoms and slows tumor growth in 
orthotopic glioma models 
A and B: 7.5 x 104 LNT-229 (A) or 105 U87MG glioma cells were implanted in the striata of CD1nu/nu mice. 
Cells were transduced with a lentivirus coding for shRNA targeted against TB4 mRNA (si), or a scrambled 
control sequence (scr). Animals (n=7 per group) were sacrificed upon onset of neurological symptoms. C: 
H&E staining of LNT-229 tumors from animals (n=3 per group) sacrificed on day 28 post implantation for 
histological analysis. Scale bar: 200 µm. 
 
Fig. 5: The differentially regulated transcriptional network in TB4-depleted glioma cells involves 
master regulators of mesenchymal transition 
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A: Transcription factors that were differentially regulated in LNT-229 glioma cells after lentiviral TB4 gene 
silencing were determined by Affymetrix gene chip analysis. Functional interactions were analyzed using the 
Search Tool for the Retrieval of Interacting Genes/Proteins (STRING). Interactions with confidence scores of 
0.9 or higher were integrated to the depicted interactome. Clusters were determined by the MCL algorithm at 
low inflation and are represented by different node colors (green, red, brown, yellow and blue). Inter-cluster 
edges are represented by dashed-lines. B: Master molecules of the transcriptional network that promotes 
mesenchymal transformation of malignant gliomas were assessed by master regulator analysis (MRA) and 
regulon analysis (DNA binding) (Carro et al. , 2010). Depicted are those genes that were at least 2-fold 
upregulated (red) or downregulated (green) after TB4 depletion in LNT-229 cells, as assessed by 
transcriptome analysis. Asterisk: Inhibitor of the mesenchymal signature.  
 
Fig. 6: TB4 gene silencing in GS-2 cells inhibits self-renewal, promotes differentiation and improves 
symptom-free survival in vivo 
A and B: Quantitative RT-PCR (A) and immunoblot (B) analysis of lentiviral TB4 gene silencing (si) relative 
to scrambled control shRNA (scr) in GS-2 neurosphere cultures. C: Acute growth assay. 5,000 GS-2 scr or si 
cells were seeded in 24-well plates and counted at indicated time points by trypan blue exclusion. D and E: 
Neurosphere formation assay. GS-2 scr or si cells were seeded at single cell dilution (1 cell / 4 µl). Sphere 
numbers (D) and volume (E) were assessed on day 21. F: Differentiation of GS-2 scr or si cells was induced 
by the addition of FCS at indicated concentrations. Cells exhibiting an adherent phenotype were quantified 
after 5 days. G: Immunocytology was performed in spheres using antibodies for nestin and GFAP. Positive 
cells were counted in at least 10 high power fields. H and I: Representative images of D-F (H), and G (I). J: 2 
x 105 GS-2 scr or si cells were implanted in the striata of CD1nu/nu mice (n=7 for each group). Animals bearing 
GS-2 scr gliomas were sacrificed upon onset of clinical symptoms. GS-2 si glioma-bearing mice did not 
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develop symptoms until day 140 (error bars: SEM; Scale bars: 100 µm (H), 50 µm (I); *p<0.05, **p<0.01, 
****p<0.0001). 
 
Fig. 7: Histological analysis of GS-2 experimental gliomas  
H&E staining (A and B) and immunohistochemistry using antibodies for nestin (C and D), GFAP (E and F) 
and NeuN (G and H). Asterisks in A indicate hemorrhage. Arrowheads in A and B indicate tumor margins. 
Scale bars: H&E, 200 µm (A and B), 50 µm (C-H). 
 
Supplementary Fig. 1: Tissue microarray (TMA), REMBRANDT and TCGA data base interrogations 
A, Glioblastoma sample, arrowheads in A depict representative tumor cells scored as TB4 high (black) and 
endothelial cells scored as TB4 low (white). Scale bars: 50 μm. B, Another glioblastoma sample, TB4 or 
GFAP staining as indicated in the left corner. TB4 is high in the tumor compartment and low in the 
endothelial compartment. Scale bar 100 μm. C and D:  TB4 immunoreactivity scores in WHO grade II-IV 
patients’ samples stratified for indicated cell types. E: TB4 immunoreactivity scores in glioblastoma stratified 
for patient age at diagnosis (cutoff: 65 years). F: TB4 immunoreactivity scores in primary vs recurrent 
glioblastoma samples (p<0.05). G: REMBRANDT interrogation for TB4 gene expression in WHO grade II-
IV patients’ samples, expressed as median mRNA expression intensity. H: TCGA survival analysis of 
patients with glioblastoma subdivided by low (n=433) versus high (n=35) TB4 mRNA expression.  
Supplementary Fig. 2: TB4 mRNA expression in glioma cell lines and in GIC. 
Normal brain control (white bars), long-term glioma cell lines (black bars) and glioma initiating cell lines 
(grey bars). qRT-PCR was performed using Arf1 as a control gene. Values are expressed as 2-ΔCT (error bars: 
SEM). 
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Supplementary Fig. 3: Lentiviral transduction efficacy. 
U87MG glioma cells were transduced with lentivirus expressing scrambled control shRNA (scr, A and B), or 
shRNA for TB4 gene silencing (si, C and D). Transduction efficacy was assessed by dsRed co-expression. 
Pictures were acquired in bright field (A and C) and red fluorescence (B and D). Scale bar: 100 µm. 
 
Supplementary Fig. 4: TB4 regulates cellular growth and metabolism in glioma cells 
A: qRT-PCR confirmation of lentiviral TB4 overexpression (TB4) as compared to empty vector controls (Ctr) 
in LNT-229 and U87MG glioma cells. B and C: 5,000 LNT-229 glioma cells were seeded per well in 24-well 
plates and counted daily by trypan blue exclusion. Cells were transduced with lentivirus for Ctr or TB4 (B), or 
for expression of shRNA targeting TB4 (si) or a scrambled control sequence (scr, C). D: 1,000 LNT-229 si 
and scr transduced cells per well were seeded in 96-well plates and Alamar blue metabolism assay was 
performed at indicated time points.  
 
Supplementary Fig. 5: TB4 gene silencing using a second shRNA target sequence confirms increased 
cell death upon serum starvation and decreased invasion 
A: qRT-PCR confirmation of lentiviral TB4 gene silencing (si_2) as compared to a scrambled control shRNA 
(scr; mean +/- SEM). B-D: 10,000 cells per well were seeded in 6-well plates overnight and cultured in 
serum-free medium for 7 days. B and C: Representative images on day 7; scale bar: 200 µm. D: LNT-229 scr 
and si_2 cells were counted manually using trypan blue for identification of dead cells. Values are expressed 
as percent of total scr (mean +/- SEM; ***p<0.001, ****p<0.0001). E-J:Lentivirally transduced LNT-229 scr 
or si_2 cells were placed in a three-dimensional collagen I matrix (E and F) and evaluated after 24 h (G and 
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H) and 48 h (I and J); scale bar in J: 200 µm. K and L: The area covered by invading cells (K), or the median 
distance invaded by the 50 most peripheral cells (L) were measured for quantitation after 48 h (mean +/- 
SEM; ***p<0.001, ****p<0.0001). 
 
Supplementary Fig. 6: TB4 gene silencing decreases migration of glioma cells 
50,000 cells per well were seeded in the upper wells of a 24-well transwell migration assay. LNT-229 and 
U87MG glioma cells were transduced with lentivirus for TB4 overexpression (TB4) or gene silencing (si), or 
with respective control viruses (Ctr, scr). Cells were allowed to migrate for 16 h (*p<0.05, **p<0.01, 
****p<0.0001). 
 
Supplementary Fig. 7: Histological analysis of LNT-229 experimental gliomas at the timepoint of 
clinical tumor progression 
H&E stainings of representative tumors were analysed upon development of clinical symptoms. LNT-229 
glioma cells were transduced with lentivirus expressing scrambled control shRNA (scr, A), or shRNA for 
TB4 gene silencing (si, B). Scale bar: 200 µm.  
 
Supplementary Fig. 8: TB4 gene silencing reduces MMP activity  
A: Lentivirally TB4-depleted (si) or scrambled control (scr) LNT-229 cells were cultured with or without 
wortmannin (WM) for 24 h. Immunoblot was performed using antibodies for ILK, Akt, β-Actin or phospho-
specific antibody to Akt-Ser473 (pAkt). B: Immunoblot of LNT-229 scr and si cells using antibodies for 
MMP2 and β-Actin. C: FRET-based MMP-activity assay (*p<0.05). 
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Supplementary Fig. 9: Inhibition of TGF-β signaling upon TB4 gene silencing 
A and B: qRT-PCR of lentivirally TB4-depleted (si) or scrambled control (scr) LNT-229 or U87MG cDNAs 
was performed using primers for TGFB1 (A) and TGFB2 (B). C and D: ELISA of LNT-229 scr and si 
conditioned media was performed using antibodies against TGF-β1 (C) and TGF-β2 (D). E: Dual 
luciferase/renilla TGF-β signaling reporter assay. LNT-229 scr and si cells were co-transfected with pRL-
CMV and either the Smad-binding element containing pGL3-SBE2-Luc (pSBE2), or the plasminogen 
activator inhibitor 1 (PAI-1) promoter containing pGL2-3TP-Luc (3TP) (scale bar: 200 µm; *p<0.05, 
**p<0.01). 
 
Supplementary video: Time-lapse recording of invading U87MG scr & U87MG siTB4 cells  
 
Supplementary Table 1 Scoring system for the assessment of clinical tumor progression.  
 
Supplementary Table 2: Clinical data and TB4 expression levels of tissue microarray patients’ samples. 
Hist: Sample histological diagnosis; Age: Age at diagnosis; Loc: Tumor localization; Res: Extent of resection; 
RTx: Radiotherapy; TMZ: Chemotherapy with Temozolomide; Other: Other systemic therapy; TB4: 
Thymosin beta4 expression levels (arbitrary units); Surv: Survival in months; A: Astrocytoma, not specified; 
FA: Fibrillary Astrocytoma; OD: Oligodendroglioma; OA: Oligoastrocytoma; XA: Pleomorphic 
Xanthoastrocytoma; AA: Anaplastic Astrocytoma; AO: Anaplastic Oligodendroglioma; AOA: Anaplastic 
Oligoastrocytoma; GA: Gemistocytic Astrocytoma; GBM: Glioblastoma, primary diagnoses of secondary 
GBMs are depicted in braces; GSR: Gliosarcoma; l: Left hemisphere; r: Right hemisphere; frt: Frontal lobe; 
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prt: Parietal lobe; tmp: Temporal lobe; occ: Occipital lobe; ins: Insula; hpc: Hippocampus; cng: Gyrus 
cinguli; tha: Thalamus; bs: Brain stem; CCNU: Lomustin; BEV: Bevacizumab; IRI: Irinotecan; GEF: 
Gefitinib; THL: Thalidomide. 
 
Supplementary Table 3 Affymetrix total mRNA expression analysis was performed in LNT-229 cells after 
TB4 gene silencing. All transcription factors and corresponding probe sets that are up-regulated (red) or 
down-regulated (green) by at least 2-fold are listed hierarchically.  
 
Supplementary Table 4 Affymetrix total mRNA expression analysis was performed in LNT-229 cells after 
TB4 gene silencing. Genes and corresponding probe sets annotated to migration by gene ontology are listed 
hierarchically.  
 
Supplementary Table 5 Affymetrix total mRNA expression analysis was performed in LNT-229 cells after 
TB4 gene silencing. Genes and corresponding probe sets annotated to apoptosis by gene ontology are listed 
hierarchically.  
 
Supplementary Table 6 Affymetrix total mRNA expression analysis was performed in LNT-229 siTB4 
cells. Differentially regulated genes were compared to the glioma signatures of up- and down-regulated genes 
defined by centroid-based clustering by Verhaak and colleagues (Verhaak et al. , 2010). Up-regulation (red) 
or gene silencing (green) by at least 2-fold in LNT-229 siTB4 is depicted by color as indicated. 
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Supplementary Table 7 Affymetrix total mRNA expression analysis was performed in LNT-229 siTB4 
cells. Differentially regulated genes were compared to the glioma gene signatures defined by Carro and 
colleagues (Carro et al. , 2010). Up-regulation (red) or gene silencing (green) by at least 2-fold in LNT-229 
siTB4 is depicted by color as indicated. 
 
Supplementary Table 8 Affymetrix total mRNA expression analysis was performed in LNT-229 siTB4 
cells. Differentially regulated genes were compared to the genes up- or down-regulated during astrocyte or 
oligodendrocyte development (Cahoy et al. , 2008). Up-regulation (red) or gene silencing (green) by at least 
2-fold in LNT-229 siTB4 is depicted by color as indicated. 
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SUPPLEMENTARY TABLE 1 
 
 
Score Clinical symptoms in mice 
 
0 
 
no visible impairment, normal gait and behaviour including 
explorative behaviour in new environment (grid, weighing scale), no 
steps missed on the grid 
 
1 no visible impairment, normal gait and behaviour including 
explorative behaviour in new environment (grid, weighing scale), 
occasional step missed on the grid, reduced activity 
 
2 reduced activity, less motile than healthy animals, reduced 
explorative behaviour, signs of discomfort (hunched back position, 
lack of grooming), reduced performance on grid, over one third of 
steps are missed, 15% weight loss compared to peak weight 
 
SUPPLEMENTARY TABLE 2  
No WHO Hist Age Loc Res RTx TMZ Other TB4 Surv 
1 II A 69 Ins, l P - -  1  
2 II A 52 Tmp, l P - -  3  
3 II FA 68 Bs P - -  0 57,9 
4 II FA 52 Frt, r P - -  2,5 24,3 
5 II FA 35 Frt-tmp, r P - +  0,5  
6 II FA 33 Frt, l P + +  1  
7 II FA 30 Frt, r T + +  2  
8 II FA 34 Bi-frt T + +  3  
9 II FA 32 Frt-tmp, l P + + CCNU 2  
10 II OD 45 Frt, l T - -  0,5  
11 II OD 30 Prt, l P + + CCNU 1  
12 II OD 30 Frt, r T - -  1  
13 II OA 61 Frt, r T + -  1,5 6,7 
14 II OA 46 Frt, l P + +  0  
15 II OA 40 Prt, l P - -  2  
16 II OA 27 Ins, r P - -  0  
17 II XA 23 Tmp, l T - -  1,5  
18 III AA 75 Ins, l T + -  2 7,6 
19 III AA 67 Cng, l T + +  3 13,9 
20 III AA 66 Frt, r P + +  2 15,3 
21 III AA 51 Hpc, l P + -  1 8,7 
22 III AA 41 Frt, l P + +  3 34,4 
23 
 
III AA 43 Tmp-prt-
frt, l 
P + +  1  
24 III AA 39 Frt, l T + +  2,5  
25 III AA 37 Hpc, r P + +  1,5  
26 III AA 38 Occ, r T + +  2  
27 III AA 37 Tmp, l P + + BEV, IRI 1 22,8 
28 III AA 30 Ins, r P - -  2  
29 III AA 24 Frt, l T + +  1  
30 III AO 73 Frt, r T + +  1,5 6,3 
31 III AO 45 Prt, l P + -  0  
32 III AO 45 Tmp, r P + -  2,5  
33 III AO 37 Frt-tmp, r P + +  1  
34 III AO 26 Ins, l P - +  1  
35 III AOA 65 Tmp, l P + +  3  
36 III AOA 57 Frt, l P + +  0  
37 III AOA 55 Prt, l P + +  1,5 29,2 
38 III AOA 43 Tmp, r T + +  2,5  
39 III AOA 35 Frt, r T + +  3  
40 III AOA 33 Frt, l P + + BEV 1,5  
41 III GA 54 Hpc, r P - -  1 5,8 
42 IV GBM 25 Prt, l P + -  3 9,9 
43 IV GBM 26 Cng, r T - + THL 3 11,1 
44 IV GBM 29 Frt, r P + -  1  
45 IV GBM 29 Tmp, l T - -  3 1,8 
46 IV GBM 30 Tmp, r P + +  0,5 10,7 
47 IV GBM 32 Tmp-prt, l P + +  3 11,5 
48 IV GBM 34 Tmp, l P + +  1,5 7,3 
49 IV GBM 35 Tmp-occ,r P + +  0,5 19,6 
50 IV GBM 37 Tmp, r T + -  3 4,2 
51 IV GBM 37 Tmp, l T + -  3  
52 IV GBM 38 Tmp-prt, r T + +  3  
53 IV GBM 40 Tmp, l P + +  2 72,1 
54 IV GBM  Prt, r P + -  1  
55 IV GBM 41 Tmp, r T + + CCNU 3 14,8 
56 IV GBM 41 Prt, r T - + CCNU 2 7,0 
57 IV GBM 44 Frt, l T + + BEV, IRI 3 16,7 
58 IV GBM 44 Prt-occ, l T + +  3 8,2 
59 IV GBM 46 Tmp, r P + +  2  
60 
 
 
IV GBM 48 Tmp, l T + + BEV, 
IRI, 
CCNU 
2 27,4 
 
61 IV GBM 48 Tmp-prt, r T - -  2,5 4,6 
62 IV GBM 48 Tmp, l T + + BEV 2 18,0 
63 IV GBM 48 Tmp, r P + + BEV, IRI 2,5 4,8 
64 
 
 
IV GBM 50 Frt, r T + + BEV, 
IRI, 
CCNU 
1,5 14,7 
 
 
65 IV GBM 50 Tmp, r P + +  2,5 16,1 
66 IV GBM 51 Tmp, r P + +  3 13,6 
67 IV GBM 52 Tmp, r T + +  3 11,8 
68 IV GBM 52 Tmp-occ,r T - + GEF 3 32,8 
69 IV GBM 54 Tmp, r T + +  3 10,2 
70 IV GBM 54 Prt-occ, r T + +  1,5 16,5 
71 IV GBM 55 Tmp, r P + +  2,5 9,4 
72 IV GBM 55 Tmp, r T + +  2 16,0 
73 IV GBM 56 Frt, r T + +  0,5 20,0 
74 IV GBM 58 Tmp, l T + + BEV, IRI 0,5 12,1 
75 IV GBM 61 Hpc, l P + +  3  
76 IV GBM 61 Prt, r P + +  0 1,8 
77 IV GBM 64 Frt, l P + +  0,5  
78 IV GBM 66 Bi-frt P + +  3 8,5 
79 
 
IV GBM 69 Frt, l P + + THL, 
GEF 
2,5 109,5 
 
80 
 
 
 
IV GBM 74 Prt-tmp, r P + + PRC, 
CCNU, 
VIN, 
GEF 
3 48,2 
 
 
 
81 
 
IV GBM 83 Tha, l P + + BEV, 
CCNU 
2 22,2 
 
82 
 
 
IV GBM 83 Frt, l P + + CCNU, 
GEF, 
BEV, IRI 
3 32,1 
 
 
83 IV GBM 88 Tmp P + +  2 4,1 
84 IV GBM 
(AOA) 
59 Tmp T + +  0,5  
85 IV GBM 
(AOA) 
38 Prt P + + GEF, 
THL 
2  
86 
 
IV GBM 
(OA) 
30 Frt-tmp, r P + +  3 12,7 
 
87 IV GSR 35 Frt, r T - -  3 15,7 
88 IV GSR 37 Tmp, l P + +  1,5 3,4 
89 IV GSR 51 Prt, r P + -  2,5 15,1          
SUPPLEMENTARY TABLE 3  
 
Transcription factors 
up-regulated down-regulated 
Probe Set ID Fold 
change 
Gene 
Symbol 
Probe Set ID Fold 
change 
Gene 
Symbol 
222171_s_at 34,90 PKNOX2 213139_at 24,75 SNAI2 
219778_at 30,02 ZFPM2 243456_at 12,07 ZNF214 
211181_x_at 16,54 RUNX1 204236_at 7,18 FLI1 
63305_at 12,88 PKNOX2 228915_at 5,49 DACH1 
211182_x_at 11,30 RUNX1 228716_at 4,47 THRB 
206261_at 7,92 ZNF239 205472_s_at 4,38 DACH1 
208502_s_at 7,74 PITX1 209242_at 4,27 PEG3 
207397_s_at 6,09 HOXD13 230472_at 4,17 IRX1 
226267_at 5,72 JDP2 209243_s_at 4,15 PEG3 
206377_at 5,55 FOXF2 209348_s_at 4,05 MAF 
236681_at 5,48 HOXD13 202672_s_at 4,04 ATF3 
1569191_at 5,13 ZNF826 201331_s_at 3,83 STAT6 
213006_at 4,37 CEBPD 206837_at 3,76 ALX1 
228462_at 3,94 IRX2 201693_s_at 3,75 EGR1 
226806_s_at 3,42 NFIA 209189_at 3,62 FOS 
203973_s_at 3,40 CEBPD 229657_at 3,58 THRB 
229638_at 3,29 IRX3 207144_s_at 3,56 CITED1 
205932_s_at 3,15 MSX1 201694_s_at 3,44 EGR1 
226590_at 3,14 ZNF618 203554_x_at 3,30 PTTG1 
221016_s_at 3,09 TCF7L1 205249_at 3,29 EGR2 
242939_at 2,93 TFDP1 228170_at 3,24 OLIG1 
204798_at 2,82 MYB 1559942_at 3,22 MDFIC 
203408_s_at 2,81 SATB1 226255_at 3,18 ZBTB33 
230438_at 2,78 TBX15 208216_at 3,11 DLX4 
204914_s_at 2,74 SOX11 207828_s_at 3,11 CENPF 
238977_at 2,74 MCM6 227261_at 2,99 KLF12 
203787_at 2,72 SSBP2 230068_s_at 2,95 PEG3 
1553172_at 2,70 ZNF777 209172_s_at 2,90 CENPF 
226695_at 2,68 PRRX1 226680_at 2,87 IKZF5 
201502_s_at 2,68 NFKBIA 226680_at 2,87 IKZF5 
238444_at 2,67 ZNF618 209357_at 2,80 CITED2 
209538_at 2,67 ZNF32 205471_s_at 2,78 DACH1 
210697_at 2,66 ZNF257 228999_at 2,68 CHD2 
223915_at 2,65 BCOR 203556_at 2,62 ZHX2 
232546_at 2,58 TP73 218849_s_at 2,60 PPP1R13L 
223916_s_at 2,56 BCOR 206029_at 2,60 ANKRD1 
210829_s_at 2,49 SSBP2 213293_s_at 2,59 TRIM22 
204915_s_at 2,48 SOX11 228038_at 2,51 SOX2 
209587_at 2,46 PITX1 203874_s_at 2,50 SMARCA1 
229956_at 2,44 NR2C1 214276_at 2,49 KLF12 
207179_at 2,44 TLX1 226420_at 2,45 EVI1 
224975_at 2,43 NFIA 207401_at 2,45 PROX1 
230511_at 2,42 CREM 235308_at 2,41 ZBTB20 
206915_at 2,41 NKX2-2 221234_s_at 2,40 BACH2 
209392_at 2,34 ENPP2 204790_at 2,38 SMAD7 
204913_s_at 2,34 SOX11 227404_s_at 2,36 EGR1 
228200_at 2,34 ZNF252 232641_at 2,36 ZNF596 
236471_at 2,29 NFE2L3 209505_at 2,34 NR2F1 
226484_at 2,28 ZBTB47 206848_at 2,34 HOXA7 
221350_at 2,27 HOXC8 202761_s_at 2,29 SYNE2 
224976_at 2,26 NFIA 209383_at 2,28 DDIT3 
210530_s_at 2,24 NR2C1 202221_s_at 2,28 EP300 
226461_at 2,23 HOXB9 201746_at 2,27 TP53 
226592_at 2,22 ZNF618 215294_s_at 2,27 SMARCA1 
234055_s_at 2,21 GZF1 203875_at 2,25 SMARCA1 
223586_at 2,20 ARNTL2 236645_at 2,21 HBP1 
224970_at 2,20 NFIA 229881_at 2,21 KLF12 
205991_s_at 2,19 PRRX1 208960_s_at 2,18 KLF6 
221703_at 2,17 BRIP1 222830_at 2,17 GRHL1 
204791_at 2,16 NR2C1 238940_at 2,16 KLF12 
218866_s_at 2,15 POLR3K 213413_at 2,16 STON1 
230440_at 2,14 ZNF469 205383_s_at 2,15 ZBTB20 
210061_at 2,14 ZNF589 238231_at 2,15 NFYC 
204039_at 2,13 CEBPA 215111_s_at 2,15 TSC22D1 
206601_s_at 2,12 HOXD3 204622_x_at 2,14 NR4A2 
239911_at 2,12 ONECUT2 216248_s_at 2,14 NR4A2 
202986_at 2,11 ARNT2 1554980_a_at 2,13 ATF3 
239412_at 2,11 IRF5 204621_s_at 2,13 NR4A2 
210062_s_at 2,08 ZNF589 235520_at 2,10 ZNF280C 
1558722_at 2,08 ZNF252 228125_at 2,10 ZNF397OS 
233446_at 2,04 ONECUT2 226991_at 2,09 NFATC2 
209710_at 2,04 GATA2 244743_x_at 2,09 ZNF138 
204702_s_at 2,03 NFE2L3 209054_s_at 2,08 WHSC1 
202490_at 2,02 IKBKAP 207069_s_at 2,08 SMAD6 
222921_s_at 2,01 HEY2 202414_at 2,07 ERCC5 
210531_at 2,00 NR2C1 223704_s_at 2,07 DMRT2 
   1555832_s_at 2,06 KLF6 
   232529_at 2,06 SP3 
   242433_at 2,04 ZBTB11 
   232231_at 2,03 RUNX2 
   205460_at 2,03 NPAS2 
   40560_at 2,03 TBX2 
   224606_at 2,02 KLF6 
   233175_at 2,01 ZNF460 
   216279_at 2,01 ZNF460 
   1562245_a_at 2,00 ZNF578    
SUPPLEMENTARY TABLE 4 
 
Gene ontology Migration 
up-regulated down-regulated 
Probe Set ID Fold change Gene Symbol Probe Set ID Fold change Gene Symbol 
202638_s_at 6,08 ICAM1 203325_s_at 6,44 COL5A1 
242517_at 5,91 KISS1R 226534_at 4,67 KITLG 
39402_at 5,35 IL1B 214702_at 3,59 FN1 
202637_s_at 4,30 ICAM1 204035_at 3,29 SCG2 
205067_at 4,13 IL1B 214701_s_at 3,19 FN1 
204351_at 3,85 S100P 1558199_at 3,07 FN1 
204563_at 3,27 SELL 212489_at 2,85 COL5A1 
212143_s_at 2,90 IGFBP3 203989_x_at 2,84 F2R 
210095_s_at 2,71 IGFBP3 209357_at 2,80 CITED2 
209355_s_at 2,71 PPAP2B 209909_s_at 2,73 TGFB2 
204844_at 2,70 ENPEP 204105_s_at 2,50 NRCAM 
223454_at 2,65 CXCL16 204105_s_at 2,50 NRCAM 
215240_at 2,48 ITGB3 204105_s_at 2,50 NRCAM 
212230_at 2,45 PPAP2B 201108_s_at 2,46 THBS1 
203381_s_at 2,39 APOE 204790_at 2,38 SMAD7 
209946_at 2,36 VEGFC 209505_at 2,34 NR2F1 
204995_at 2,28 CDK5R1 235086_at 2,28 THBS1 
215485_s_at 2,26 ICAM1 229114_at 2,25 GAB1 
218629_at 2,16 SMO 212298_at 2,24 NRP1 
204363_at 2,14 F3 201109_s_at 2,19 THBS1 
239911_at 2,12 ONECUT2 212488_at 2,19 COL5A1 
213030_s_at 2,05 PLXNA2 202803_s_at 2,18 ITGB2 
233446_at 2,04 ONECUT2 239233_at 2,17 CCDC88A 
   212144_at 2,14 UNC84B 
   225806_at 2,11 JUB 
   1553764_a_
at 
2,08 JUB 
   210495_x_at 2,06 FN1 
   212464_s_at 2,06 FN1 
   216442_x_at 2,02 FN1     
SUPPLEMENTARY TABLE 5 
 
Gene ontology Apoptosis 
up-regulated down-regulated 
Probe Set ID Fold change Gene Symbol Probe Set ID Fold change Gene Symbol 
216598_s_at 11,73 CCL2 202036_s_at 7,46 SFRP1 
204933_s_at 7,85 TNFRSF11B 218499_at 7,36 RP6-
213H19.1 
205681_at 7,74 BCL2A1 202037_s_at 7,36 SFRP1 
215223_s_at 7,36 SOD2 203139_at 6,62 DAPK1 
1566342_at 6,07 SOD2 202035_s_at 5,92 SFRP1 
204932_at 5,98 TNFRSF11B 226534_at 4,67 KITLG 
216841_s_at 5,80 SOD2 209242_at 4,27 PEG3 
210538_s_at 5,80 BIRC3 209243_s_at 4,15 PEG3  
39402_at 5,35 IL1B 209031_at 3,81 CADM1 
203528_at 5,05 SEMA4D 1554264_at 3,74 CKAP2 
221477_s_at 4,72 SOD2 209032_s_at 3,59 CADM1 
228153_at 4,46 RNF144B 204035_at 3,29 SCG2 
205067_at 4,13 IL1B 224985_at 2,97 NRAS 
204224_s_at 4,12 GCH1 230068_s_at 2,95 PEG3 
227143_s_at 3,96 BID 203989_x_at 2,84 F2R 
204513_s_at 3,86 ELMO1 209357_at 2,80 CITED2 
210118_s_at 3,77 IL1A 203373_at 2,75 SOCS2 
204493_at 3,59 BID 209909_s_at 2,73 TGFB2 
202643_s_at 3,28 TNFAIP3 237107_at 2,70 PRKRAP1 
202644_s_at 3,16 TNFAIP3 209030_s_at 2,61 CADM1 
205932_s_at 3,15 MSX1 218849_s_at 2,60 PPP1R13L 
205047_s_at 3,07 ASNS 201291_s_at 2,47 TOP2A 
212143_s_at 2,90 IGFBP3 201108_s_at 2,46 THBS1 
1554830_a_
at 
2,83 STEAP3 230380_at 2,41 THAP2 
211725_s_at 2,81 BID 202512_s_at 2,40 ATG5 
210095_s_at 2,71 IGFBP3 204790_at 2,38 SMAD7 
233011_at 2,68 ANXA1 223349_s_at 2,35 BOK 
201502_s_at 2,68 NFKBIA 221478_at 2,33 BNIP3L 
232546_at 2,58 TP73 201292_at 2,29 TOP2A 
211475_s_at 2,56 BAG1 209383_at 2,28 DDIT3 
216252_x_at 2,44 FAS 235086_at 2,28 THBS1 
212196_at 2,41 IL6ST 202221_s_at 2,28 EP300 
218424_s_at 2,40 STEAP3 201746_at 2,27 TP53 
203381_s_at 2,39 APOE 203372_s_at 2,23 SOCS2 
215719_x_at 2,37 FAS 205858_at 2,23 NGFR 
216705_s_at 2,34 ADA 225858_s_at 2,22 XIAP 
204995_at 2,28 CDK5R1 237469_at 2,20 TOP2A 
204863_s_at 2,25 IL6ST 201109_s_at 2,19 THBS1 
213257_at 2,20 SARM1 223257_at 2,18 G2E3 
221583_s_at 2,20 KCNMA1 202803_s_at 2,18 ITGB2 
204639_at 2,18 ADA 206189_at 2,17 UNC5C 
218629_at 2,16 SMO 228363_at 2,13 XIAP 
212195_at 2,16 IL6ST 1555675_at 2,08 BLID 
211450_s_at 2,15 MSH6 207069_s_at 2,08 SMAD6 
204363_at 2,14 F3 202414_at 2,07 ERCC5 
218627_at 2,11 DRAM 221479_s_at 2,04 BNIP3L 
211000_s_at 2,10 IL6ST 223254_s_at 2,01 G2E3 
207199_at 2,09 TERT 
207536_s_at 2,09 TNFRSF9 
1552519_at 2,08 ACVR1C 
223322_at 2,06 RASSF5 
203619_s_at 2,05 FAIM2 
218380_at 2,05 NLRP1 
220999_s_at 2,05 CYFIP2 
204352_at 2,04 TRAF5  
SUPPLEMENTARY TABLE 6 
 
Verhaak et al. 2010 
 
up-regulated / down-regulated  
 
Proneural Mesenchymal Classical 
 
up down up down up down 
CLGN SLC2A10 BNC2 CDK5R1 ELOVL2 PGBD5 
PDE10A DRAM COL1A1 MAPT SMO TPM3 
LPHN3 ANXA1 CTSC ANKRD46 TLE2 ENPP4 
NKX2-2 FZD7 CSTA CLASP2 MYO10 ARRB1 
SATB1 GJA1 TRPM2 SOX2 CDK6 ENPP2 
SOX11 ARSJ ACPP MAP2 FGFR3 SYNGR2 
FLRT1 PLS3 TNFAIP3 CKB SOCS2 EDIL3 
MYB TRIM22 BDKRB2 TSPAN3 LFNG GNAI1 
MCM10  AIM1  KLHL4 ACSL4 
CDC25A  COL5A1   
HOXD3  COL1A2   
ALCAM  THBS1   
FHOD3  NRP1   
FAM110B  SLC16A3   
HMGB3  DAB2   
MARCKS  DSE   
BCOR  LAPTM5   
  ITGB2   
  STAT6   
  RUNX2        
SUPPLEMENTARY TABLE 7 
 
Carro et al. 2010 
 
up-regulated / down-regulated 
 
Proneural Mesenchymal Proliferative 
SCD IFITM2 MCM6 
GABBR1 ICAM1 RAD51 
APOE FBN1 CCNE2 
MAPT TAGLN GINS1 
ALDH5A1 RUNX1 ARNTL2 
FAIM2 CA12 TIFA 
ELMO1 C1R ITGA2 
BMP2 STEAP3 NPHP1 
MAPT PAPPA DLGAP5 
FLRT1 METTL7B AURKA 
SLITRK5 SPOCD1 NEK2 
CYFIP2 SLC16A3 TOP2A 
FERMT1 LPAR1 NDC80 
HEY2 NRP1 CKS2 
RASSF4 COL4A1 TTK 
PKNOX2 COL4A2 CENPA 
NTN4 PELO CENPE 
TMOD2 SHROOM3 CDC25C 
LOC202451 EMP1 KIF14 
KSR2  HMMR 
FGF13  CENPF 
OMG  BUB1 
MAF  MDFIC 
ZCCHC24  CCNB1 
FAM110B  ECT2 
IKZF5  ASPM 
OLIG1  NUSAP1 
NALCN  KIF18A 
RPL13  NUF2 
CNTN3  SPIN4 
FAM133A  SGOL2 
FSTL5  hCG_181549  
SUPPLEMENTARY TABLE 8 
 
Cahoy et al. 2008 
 
up-regulated / down-regulated 
 
Astrocyte  
 
Oligodendrocyte  
up down up down 
OMG MARCKS TTYH2 F2R 
NPAS2 PDZRN3 DBNDD2 FSTL5 
RHOU FSTL5 PARVB MKI67 
 EGR2 APOD LPHN3 
 NR4A2  SOX11 
 GAS2L3   
 CENPA   
 CDCA8   
 ECT2   
 PRC1   
 CEP55   
 TOP2A   
 MKI67   
 CKS2   
 CCNB2   
 BUB1   
 CENPF   
 CCNB1   
 H19   
 EMP1   
 MCM6   
 PTX3    
